Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Given Average Recommendation of “Reduce” by Analysts

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has earned a consensus rating of “Reduce” from the six research firms that are covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $3.42.

Several analysts recently issued reports on DNA shares. BTIG Research boosted their target price on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the company a “sell” rating in a research report on Friday, August 23rd. TD Cowen boosted their price objective on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the company a “buy” rating in a research report on Friday. Finally, The Goldman Sachs Group reduced their price objective on Ginkgo Bioworks from $0.02 to $0.01 and set a “sell” rating for the company in a research note on Tuesday, July 9th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. lifted its position in shares of Ginkgo Bioworks by 28.2% in the fourth quarter. Victory Capital Management Inc. now owns 178,165 shares of the company’s stock valued at $301,000 after acquiring an additional 39,171 shares in the last quarter. National Bank of Canada FI boosted its stake in Ginkgo Bioworks by 142.0% in the 4th quarter. National Bank of Canada FI now owns 30,672 shares of the company’s stock worth $51,000 after purchasing an additional 18,000 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Ginkgo Bioworks by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 7,661,303 shares of the company’s stock valued at $12,948,000 after buying an additional 242,906 shares in the last quarter. Brown Advisory Inc. raised its position in shares of Ginkgo Bioworks by 17.2% during the fourth quarter. Brown Advisory Inc. now owns 239,425 shares of the company’s stock valued at $405,000 after buying an additional 35,182 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Ginkgo Bioworks in the fourth quarter worth $24,967,000. Institutional investors own 78.63% of the company’s stock.

Ginkgo Bioworks Price Performance

NYSE DNA opened at $8.01 on Tuesday. The stock has a market capitalization of $17.71 billion, a price-to-earnings ratio of -18.20 and a beta of 1.06. Ginkgo Bioworks has a 1-year low of $5.26 and a 1-year high of $82.80. The business’s fifty day moving average price is $3.20 and its 200-day moving average price is $1.13.

Ginkgo Bioworks (NYSE:DNA) last posted its earnings results on Thursday, August 8th. The company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). The company had revenue of $56.21 million for the quarter, compared to the consensus estimate of $41.46 million. Ginkgo Bioworks had a negative return on equity of 63.09% and a negative net margin of 486.98%. Equities research analysts anticipate that Ginkgo Bioworks will post -12.6 EPS for the current year.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.